Skip to content

Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health

Cannabis Use | Marijuana Use

With perinatal cannabis use rising in Canada, robust data on short-term and long-term effects on newborns are urgently needed. However, past barriers to obtain robust data included limited sample sizes, low self-reporting and no account of postpartum exposures. Therefore, this study will be conducted as a feasibility pilot study to tease out limitations that were present in previous studies. This study will help us dictate how to conduct a larger prospective cohort study to answer any knowledge gaps currently in the field of perinatal cannabis use.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    16 and up

Participation Criteria

MOTHER INFANT DYADS

Inclusion Criteria:

Exposed and unexposed pregnant women/individuals must meet all of the following inclusion criteria at the time of enrollment to be eligible:

* Capacity to provide informed consent and to comprehend and comply with the study requirements
* Planning to deliver at TOH or KGH, or The Ottawa Birth and Wellness Centre (affiliated with TOH)
* Be ≥ 16 years of age at the time of consent

Exposed group: pregnant women/individuals who are using any cannabis-related product in pregnancy at the time of enrollment, or have used cannabis-related products in the current pregnancy for any reason (including but not limited to recreational use, to ease nausea and vomiting, use for chronic pain management or other medical indications).

Unexposed group: pregnant women/individuals who are not using cannabis-related products in pregnancy, and who have not used any cannabis-related product for at least 3-months prior to pregnancy.

Exclusion Criteria:

* Women/Individuals who self-report non-prescription use of controlled and illegal drugs in their current pregnancy (i.e., benzodiazepines, cocaine and crack, fentanyl, heroin, ketamine, lysergic acid diethylamide, magic mushrooms, MDMA, methamphetamine, gamma hydroxybutyrate, opioids, phenylcyclohexyl piperidine, salvia) or report their use in the 3-months prior to pregnancy. (\*\*Use of alcohol or tobacco products prior to pregnancy or during pregnancy will not be an exclusion criterion\*\*)
* Women/Individuals who self-report prescription use of opioid medications including methadone, Subutex, buprenorphine, tramadol, oxycodone, hydrocodone, and hydromorphine in their current pregnancy, or report their use in the 3 months prior to pregnancy
* Surrogate or planning to give child up for adoption

PARTNERS 'Partner' will be broadly defined as any individual identified as such by an enrolled pregnant participant (any sex or gender, any status - marital, common-law, or otherwise). Thus, eligible partners must meet all of the following inclusion criteria at the time of enrollment:

* Pregnant partner is enrolled in the CUPiD cohort study
* Have capacity to provide informed consent and to comprehend and comply with the study requirements
* Be ≥ 16 years of age at the time of consent

There are no pre-defined exclusion criteria for partners.

Study Location

The Ottawa Hospital - Civic Campus
The Ottawa Hospital - Civic Campus
Ottawa, Ontario
Canada

Contact Study Team

Backup Contact

Alysha Harvey, MSc, PMP

[email protected]
613-737-8899
Primary Contact

Serine Ramlawi, MSc

[email protected]
613-737-8899
Children's Hospital of Eastern Ontario
Children's Hospital of Eastern Ontario
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Serine Ramlawi, MSc

[email protected]
613-737-8899
Backup Contact

Alysha Harvey, MSc, PMP

[email protected]
613-737-8899
The Ottawa Hospital - General Campus
The Ottawa Hospital - General Campus
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Serine Ramlawi, MSc

[email protected]
613-737-8899
Backup Contact

Alysha Harvey, MSc, PMP

[email protected]
613-737-8899
Kingston Health Sciences Centre
Kingston Health Sciences Centre
Kingston, Ontario
Canada

Contact Study Team

Primary Contact

Laura Gaudet, MD

[email protected]
Backup Contact

Jessica Pudwell, MSc, MPH

[email protected]
Study Sponsored By
Ottawa Hospital Research Institute
Participants Required
More Information
Study ID: NCT05309226